Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Director | May 06, 2019 | May 08, 2019 |
| CHURCH & DWIGHT CO INC /DE/CHD · Entity 2509 | Director | July 01, 2026 | July 02, 2026 |
| DENTSPLY SIRONA Inc.XRAY · Entity 4448 | Director | June 03, 2026 | June 05, 2026 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | June 05, 2025 | June 09, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date May 06, 2019 · Filed May 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 18,257 |
Reported balance
After 2019-05-08 transaction · row 1
1 source rowRow 1 · 2019-05-08 · Exercise / conversion · Acquired 6,107 · Balance 18,257 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $14.05 · Expires 2029-05-06 | Direct | 28,044 |
Reported balance
After 2019-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-06 · Grant · Acquired 28,044 · Balance 28,044 F2: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,459 |
Reported balance
After 2019-05-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-06 · Grant · Acquired 6,459 · Balance 6,459 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-05-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-05-08 · Exercise / conversion · Disposed 6,107 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
F3: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date.
F4: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019.
CHURCH & DWIGHT CO INC /DE/
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,188 |
Reported balance
After 2026-07-01 transaction · row 1
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 736 · Balance 21,188 |
DENTSPLY SIRONA Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,324 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 22,822 · Balance 67,324 F1: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date June 05, 2025 · Filed June 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 73,697 |
Reported balance
After 2025-06-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-06 · Exercise / conversion · Acquired 9,632 · Balance 73,697 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-06-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-06 · Exercise / conversion · Disposed 9,632 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 14,492 |
Reported balance
After 2025-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-05 · Grant · Acquired 14,492 · Balance 14,492 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025.
F4: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Impax Laboratories, LLC
Report date May 04, 2018 · Filed May 08, 2018
Section 16 reporting ended · disclosed 2018-05-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 1
1 source rowRow 1 · 2018-05-04 · Disposition to issuer · Disposed 6,642 · Balance 0 F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). |
| Restricted Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 2
1 source rowRow 2 · 2018-05-04 · Disposition to issuer · Disposed 5,508 · Balance 0 F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.40 · Expires 2027-05-16 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-04 · Disposition to issuer · Disposed 10,575 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.33 · Expires 2026-05-17 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-04 · Disposition to issuer · Disposed 10,575 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.42 · Expires 2025-10-07 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-04 · Disposition to issuer · Disposed 8,100 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock").
F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock.
F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2021 Filed Jul 13, 2021 20:11 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 5.156 | $64.18 | $330.91 |
DisclosureSEC source: 0001127602-21-021873 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,846.484 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 15:13 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantCommon Stock | 1,409 | $85.22 | $120,074.98 |
DisclosureSEC source: 0001127602-21-020930 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,350 Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 16:12 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantStock Option · Derivative | 7,850 | $0.00 Strike: $84.54 | $0.00 |
DisclosureSEC source: 0001127602-21-019862 · form4.xml · derivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,850 Underlying: Common Stock · 7,850 shares Expires 2031-06-14 Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 12:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 14,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040815 · doc4.xml · derivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,479 Underlying: Ordinary Shares · 14,479 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022. F2 · derivative.expiration_date: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 11:47 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 12,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039375 · doc4.xml · derivative · entry 2 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 9, 2020 and vested on June 9, 2021. F3 · derivative.expiration_date: Restricted share units were granted on June 9, 2020 and vested on June 9, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 11:47 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 12,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-039375 · doc4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 20:45 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 3,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-018527 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,841.328 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 21:35 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 7.828 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-013658 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,833.328 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:39 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 9.24 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-001516 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,825.5 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 19:55 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 15.681 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-026856 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,816.26 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 15:41 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | Exercise / conversionStock Option · Derivative | 14,660 | $0.00 Strike: $41.92 | $0.00 |
DisclosureSEC source: 0001127602-20-022801 · form4.xml · derivative · entry 3 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,660 shares Expires 2025-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 15:41 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | SaleCommon Stock | 14,660 | $95.58 | $1,401,268.77 |
DisclosureSEC source: 0001127602-20-022801 · form4.xml · nonDerivative · entry 2 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,941 F1 · price: The price in Column 4 is a weighted average price. The prices actually paid in this transaction range from $95.51 to $95.695. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 15:41 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | Exercise / conversionCommon Stock | 14,660 | $41.92 | $614,473.90 |
DisclosureSEC source: 0001127602-20-022801 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2020 Filed Jul 10, 2020 21:03 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 15.735 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-021360 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800.579 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 18:13 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantCommon Stock | 1,553 | $77.30 | $120,046.90 |
DisclosureSEC source: 0001127602-20-020580 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,941 Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 18:17 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantStock Option · Derivative | 10,950 | $0.00 Strike: $73.87 | $0.00 |
DisclosureSEC source: 0001127602-20-019683 · form4.xml · derivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,950 Underlying: Common Stock · 10,950 shares Expires 2030-06-15 Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 11:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 12,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035790 · doc4.xml · derivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,668 Underlying: Ordinary Shares · 12,668 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 9, 2020 and vest on June 9, 2021. F2 · derivative.expiration_date: Restricted share units were granted on June 9, 2020 and vest on June 9, 2021. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 21, 2020 Filed May 22, 2020 20:28 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 4,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-017781 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,784.844 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| April 10, 2020 Filed Apr 14, 2020 20:30 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 5.308 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-013711 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,018.844 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 21:47 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 3.536 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-001565 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,013.536 F1 · shares: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:21 UTC | DENTSPLY SIRONA Inc. XRAY · Entity 4448 | GrantCommon Stock | 2,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-034947 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,010 F1 · shares: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant. Read SEC document |
| November 05, 2019 Filed Nov 6, 2019 13:12 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | PurchaseCommon Stock | 300 | $67.19 | $20,158.17 |
DisclosureSEC source: 0001127602-19-031980 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,388 Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 17:32 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantCommon Stock | 753 | $73.06 | $55,014.18 |
DisclosureSEC source: 0001127602-19-023113 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,088 Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 18:05 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantStock Option · Derivative | 8,600 | $0.00 Strike: $77.33 | $0.00 |
DisclosureSEC source: 0001127602-19-021976 · form4.xml · derivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,600 Underlying: Common Stock · 8,600 shares Expires 2029-06-17 Read SEC document |
| May 08, 2019 Filed May 8, 2019 21:47 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 6,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000068 · wf-form4_155735201312225.xml · derivative · entry 4 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. Read SEC document |
| May 08, 2019 Filed May 8, 2019 21:47 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 6,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001723128-19-000068 · wf-form4_155735201312225.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:47 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000068 · wf-form4_155735201312225.xml · derivative · entry 3 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 Underlying: Class A Common Stock · 6,459 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:47 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 28,044 | $0.00 Strike: $14.05 | $0.00 |
DisclosureSEC source: 0001723128-19-000068 · wf-form4_155735201312225.xml · derivative · entry 2 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,044 Underlying: Class A Common Stock · 28,044 shares Expires 2029-05-06 F2 · derivative.exercise_date: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| November 06, 2018 Filed Nov 6, 2018 16:47 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | Exercise / conversionStock Option · Derivative | 15,762 | $0.00 Strike: $34.04 | $0.00 |
DisclosureSEC source: 0001127602-18-032196 · form4.xml · derivative · entry 3 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,762 shares Expires 2024-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2018 Filed Nov 6, 2018 16:47 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | SaleCommon Stock | 15,762 | $66.54 | $1,048,734.13 |
DisclosureSEC source: 0001127602-18-032196 · form4.xml · nonDerivative · entry 2 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,335 F1 · price: The price in Column 4 is a weighted average price. The prices actually paid in this transaction range from $66.47 to $66.5822. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. Read SEC document |
| November 06, 2018 Filed Nov 6, 2018 16:47 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | Exercise / conversionCommon Stock | 15,762 | $34.04 | $536,459.67 |
DisclosureSEC source: 0001127602-18-032196 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 13:18 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantCommon Stock | 2,070 | $53.16 | $110,041.20 |
DisclosureSEC source: 0001127602-18-022393 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,335 Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 12:55 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantStock Option · Derivative | 13,200 | $0.00 Strike: $50.28 | $0.00 |
DisclosureSEC source: 0001127602-18-021267 · form4.xml · derivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2028-06-18 Read SEC document |
| May 07, 2018 Filed May 8, 2018 23:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 6,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-011950 · doc4.xml · derivative · entry 6 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,107 Underlying: Class A Common Stock · 6,107 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. F6 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. Read SEC document |
| May 07, 2018 Filed May 8, 2018 23:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 24,977 | $0.00 Strike: $15.01 | $0.00 |
DisclosureSEC source: 0000899243-18-011950 · doc4.xml · derivative · entry 5 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,977 Underlying: Class A Common Stock · 24,977 shares Expires 2028-05-07 F4 · derivative.exercise_date: The option vests in four equal annual installments beginning on May 07, 2019. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:30 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,100 | Not disclosed Strike: $38.42 | Not disclosed |
DisclosureSEC source: 0001003642-18-000089 · wf-form4_152581134784107.xml · derivative · entry 5 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,100 shares Expires 2025-10-07 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:30 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,575 | Not disclosed Strike: $30.33 | Not disclosed |
DisclosureSEC source: 0001003642-18-000089 · wf-form4_152581134784107.xml · derivative · entry 4 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,575 shares Expires 2026-05-17 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:30 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,575 | Not disclosed Strike: $16.40 | Not disclosed |
DisclosureSEC source: 0001003642-18-000089 · wf-form4_152581134784107.xml · derivative · entry 3 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,575 shares Expires 2027-05-16 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:30 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerRestricted Common Stock | 5,508 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003642-18-000089 · wf-form4_152581134784107.xml · nonDerivative · entry 2 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. F2 · price: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:30 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerCommon Stock | 6,642 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003642-18-000089 · wf-form4_152581134784107.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). F1 · price: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 8,100 | Not disclosed Strike: $38.42 | Not disclosed |
DisclosureSEC source: 0000899243-18-011950 · doc4.xml · derivative · entry 4 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,100 Underlying: Class A Common Stock · 8,100 shares Expires 2025-10-07 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 10,575 | Not disclosed Strike: $30.33 | Not disclosed |
DisclosureSEC source: 0000899243-18-011950 · doc4.xml · derivative · entry 3 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,575 Underlying: Class A Common Stock · 10,575 shares Expires 2026-05-17 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 10,575 | Not disclosed Strike: $16.40 | Not disclosed |
DisclosureSEC source: 0000899243-18-011950 · doc4.xml · derivative · entry 2 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,575 Underlying: Class A Common Stock · 10,575 shares Expires 2027-05-16 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantClass A Common Stock | 12,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-011950 · doc4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,150 F1 · price: Received in exchange for 12,150 shares of Impax Laboratories, Inc. ("Impax") common stock pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax, Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (as amended, the "BCA"). Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 16:23 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantCommon Stock | 2,121 | $51.88 | $110,037.48 |
DisclosureSEC source: 0001127602-17-022717 · form4.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,265 Read SEC document |
| June 19, 2017 Filed Jun 20, 2017 16:46 UTC | CHURCH & DWIGHT CO INC /DE/ CHD · Entity 2509 | GrantStock Option · Derivative | 11,590 | $0.00 Strike: $53.75 | $0.00 |
DisclosureSEC source: 0001127602-17-021851 · form4.xml · derivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,590 Underlying: Common Stock · 11,590 shares Expires 2027-06-19 Read SEC document |
| May 16, 2017 Filed May 17, 2017 15:46 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantStock Option (Right-to-Buy) · Derivative | 10,575 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001003642-17-000050 · wf-form4_149505040302432.xml · derivative · entry 2 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,575 Underlying: Common Stock · 10,575 shares Expires 2027-05-16 F1 · derivative.exercise_date: The option fully vests on the earlier of (i) May 16, 2018 which is the first anniversary of the date of grant and (ii) one day before the date of the Company's next annual meeting of stockholders. Read SEC document |
| May 16, 2017 Filed May 17, 2017 15:46 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantCommon Stock | 4,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001003642-17-000050 · wf-form4_149505040302432.xml · nonDerivative · entry 1 Vergis Janet S. · CIK 0001590794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,150 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.